![Expanding Glucagon Access and Use in the Prehospital Setting - JEMS: EMS, Emergency Medical Services - Training, Paramedic, EMT News Expanding Glucagon Access and Use in the Prehospital Setting - JEMS: EMS, Emergency Medical Services - Training, Paramedic, EMT News](https://images.jems.com/wp-content/uploads/2018/08/1808JEMSkah-p01-Eli-Lilly-Glucagon.png)
Expanding Glucagon Access and Use in the Prehospital Setting - JEMS: EMS, Emergency Medical Services - Training, Paramedic, EMT News
![Prescribing Information for Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors (Based on US Labels) | Radcliffe Cardiology Prescribing Information for Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors (Based on US Labels) | Radcliffe Cardiology](https://assets.radcliffecardiology.com/s3fs-public/article/2021-03/table2-prescribing-information.png)
Prescribing Information for Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors (Based on US Labels) | Radcliffe Cardiology
Expanding Glucagon Access and Use in the Prehospital Setting - JEMS: EMS, Emergency Medical Services - Training, Paramedic, EMT News
GLUCAGON AGENTS; Current Product Listing. LABEL NAME GENERIC NAME MANUFACTURER DRUG TYPE PROVIDER SYNERGIES BRAND NAME ROUTE BAQ
![Expanding Glucagon Access and Use in the Prehospital Setting - JEMS: EMS, Emergency Medical Services - Training, Paramedic, EMT News Expanding Glucagon Access and Use in the Prehospital Setting - JEMS: EMS, Emergency Medical Services - Training, Paramedic, EMT News](https://images.jems.com/wp-content/uploads/2018/08/1808JEMSkah-p02-Xeris-glucagon.png)
Expanding Glucagon Access and Use in the Prehospital Setting - JEMS: EMS, Emergency Medical Services - Training, Paramedic, EMT News
![Xeris Doses First Patient in Phase 2 Study of Mini-dose Glucagon for mild-moderate hypoglycemia in T1D patients Xeris Doses First Patient in Phase 2 Study of Mini-dose Glucagon for mild-moderate hypoglycemia in T1D patients](https://diatribe.org/cdn-cgi/image/width=400/sites/default/files/images/GPEN%20Mini%20Model%20Xeris.jpg)
Xeris Doses First Patient in Phase 2 Study of Mini-dose Glucagon for mild-moderate hypoglycemia in T1D patients
![GVOKE (glucagon injection) Xeris Pharmaceuticals, Inc. These highlights do not include all the information needed to use GVOKE safely and effectively. See full prescribing information for GVOKE. GVOKE (glucagon injection), for subcutaneous GVOKE (glucagon injection) Xeris Pharmaceuticals, Inc. These highlights do not include all the information needed to use GVOKE safely and effectively. See full prescribing information for GVOKE. GVOKE (glucagon injection), for subcutaneous](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=72065-121-11_AI_Pouch_1mg.jpg&id=685359)